Journal of Cancer Research and Therapeutics Close
 

Figure 3: Rank probabilities plot of effect of monoclonal antibody check point inhibitors on survival given first line in Nonsmall cell lung cancer. (a) Check point inhibitors and first line overall survival, (b) Check point inhibitors and first line progression-free survival (Che=Chemotherapy, Ate=Atezolizumab, Ic=Ipilimumab concurrent, Ip=Ipilimumab phased, Pem=Pembrolizumab, Niv=Nivolumab, Niv + I=Nivolumab + Ipilimumab. Higher rank numbers imply higher efficacy)

Figure 3: Rank probabilities plot of effect of monoclonal antibody check point inhibitors on survival given first line in Nonsmall cell lung cancer. (a) Check point inhibitors and first line overall survival, (b) Check point inhibitors and first line progression-free survival (Che=Chemotherapy, Ate=Atezolizumab, Ic=Ipilimumab concurrent, Ip=Ipilimumab phased, Pem=Pembrolizumab, Niv=Nivolumab, Niv + I=Nivolumab + Ipilimumab. Higher rank numbers imply higher efficacy)